PUBLIC COMPANY
saveHikma Pharmaceuticals Plc
updated 12d ago
Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
community read0 votes
🐶 often sniffed alongside
top 8- companyHikma Pharmaceuticals USA Inc4 co-mentions · 4 sources
- tagApproval4 co-mentions · 2 sources
- drugENOBY4 co-mentions · 2 sources
- tagRecall2 co-mentions · 2 sources
- drugdenosumab2 co-mentions · 2 sources
- drugXgeva2 co-mentions · 2 sources
- druglorazepam ER1 co-mentions · 1 sources
- drugMETHADONE HYDROCHLORIDE1 co-mentions · 1 sources
pipeline
10
marketed
4
phase 3
0
catalysts ytd
20
approvals ytd
19
recalls ytd
0
Pipeline(10)
pipeline depth10 products
4Marketed6Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- N/AExtension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
- phase1Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
- —Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
- —Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
- phase2Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- —Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
- —Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
🐶 Hiring Signal
News
- Generic drugmakers gain key victory in ‘skinny label’ patent caseThe Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.biopharma_dive · 2mo ago
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseThe Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.stat · 2mo ago
- Supreme Court sides with Hikma in 'skinny label' caseThe Supreme Court unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by the generics industry. T…endpoints · 2mo ago
- STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and moreAstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spendingstat · 3mo ago
- STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and moreThe FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgenstat · 3mo ago
- Pfizer deals extend patent life for a top-selling rare disease drugSettlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.biopharma_dive · 3mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that